ESR1 and neoplasm: In addition to two poor prognoses ER+ tumors, BCCS presented two good prognoses ER+ subtypes, PCS1 and PCS4, that exhibited significantly different features with respect to gene expression, mutation frequency, copy number changes, tumor cellularity, and promoter methylation of ESR1.